Chairman of the Medical Advisory Committee

Dr. Parkash S. Gill, M.D. is the Chairman of the Medical Advisory Board in support of mesothelioma treatment and cancer cure.
Dr. Parkash S. Gill, M.D.

Dr. Gill is a professor of Medicine and Pathology at the Keck School of Medicine of USC; head of the tumor and vascular biology laboratory at the University of Southern California; the Leader of the Translational and Clinical Sciences Program at the USC Norris Comprehensive Cancer Center, and the Ezalow Family Chair in Cancer Therapeutics.

Dr. Gill's laboratory has an active translational program to develop cancer therapeutics based on "basic" or classic bench research. His translational work has broad application for a number of cancers including Kaposi's sarcoma, ovarian cancer, prostate and bladder cancer, colon cancer, mesothelioma, and head and neck cancer. His clinical investigations have given him unique insights and led to FDA approval of three novel cancer therapies.

The paring of Dr. Gills's translational work and clinical investigation has generated new understanding of disease progression and biology. Based on thoughtful and broad studies, Dr. Gill has identified novel cancer and cancer blood vessel targets.Using his research and validation of therepeutic proteins and antibodies, Dr. Gill has defined the role of EphB4 recepter tyrosine kinase and its protein EphrinB2 as a novel tumor target in certain cancers. He has initiated first-in-human clinical studies in cancers of the prostate, lung, head and neck, and breast. Dr. Gill is attuned to the needs of the patient population served by USC Norris and LAC+USC Medical Center. He has begun to explore the role of other highly expressed molecular targets including VEGF/VEGFRs, ligand DLL4 for Notch receptors, Axl tyrosine kinase receptor, and GRP78.

Dr. Gill's research interests include: tumor cell biology, tumor vessel development & Identification; clinical research in Mesothelioma, leukemia, lymphoma, and sarcoma; clinical and molecular features of disease outcome and development of novel therapeutics in Mesothelioma, leukemia, lymphoma, and sarcoma; clinical trials in Rx of Mesothelioma, leukemia, lymphoma and sarcoma.

Board Certification

  • American Board of Internal Medicine, 1982
  • Medical Oncology, 1987

Educational background

  • Doctor of Medicine, Medicine Government Medical College, June 1, 1974
  • Residency, New Brunswick Affiliated Hospitals, N.J. 1977-83
  • Fellowship, LAC & USC Medical Center - Hematology, 1981-83

Professional Society Memberships

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for the Advancement of Science

Back to biographies